TRPA1 polymorphisms associated with neuropathic pain in a Spanish population with complete spinal cord injury. An early phase study.
Vidal Rodríguez S, Castillo I.
Spinal Cord Injury J 2017 (en prensa)
COL1A1, COL5A1 and GDF5 polymorphisms associated with rotator cuff disease
Vidal Rodríguez S, Castillo I.
Bone Joint J Apr 2017, 99-B (SUPP 8) 40;
Occult hepatitis C virus infection in patients with diabetic nephropathy: epidemiological and clinical implications.
Olea T, Castillo I, González E, Rodríguez-Gayo L, Bartolomé J, Vaca M, Quiroga JA, Madero R, Selgas R, Carreño V.
World J Res Rev (WJRR) 2016 Dic;3(6): 65-9.
Detection of hepatitis C virus (HCV) core-specific antibody suggests occult HCV infection among blood donors.
Quiroga JA, Avellón A, Bartolomé J, Andréu M, Flores E, González MI, González R, Pérez S, Richart LA, Castillo I, Alcover J, Palacios R, Carreño V, Echevarría JM.
Transfusion. 2016 Jul;56(7):1883-90.
Ver en: http://onlinelibrary.wiley.com/doi/10.1111/trf.13645/abstract
Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection.
Bartolomé J, Castillo I, Quiroga JA, Carreño V. J Med Virol. 2016 Feb;88(2):268-74
Ver en: http://onlinelibrary.wiley.com/doi/10.1002/jmv.24322/abstract
Impact of Isolated Hepatitis C Virus (HCV) Core-Specific Antibody Detection and Viral RNA Amplification among HCV-Seronegative Dialysis Patients at Risk for Infection
Guillermina Barril, Juan A. Quiroga, María Dolores Arenas, Mario Espinosa, Nuria García-Fernández, Secundino Cigarrán, José A. Herrero, Gloria del Peso, Pilar Caro, Rebeca García-Agudo, Yésica Amézquita, Ana Blanco, Pilar Martínez-Rubio, José M. Alcázar, Emilio González-Parrao, Adoración Martín-Gómez, Inmaculada Castillo, Javier Bartolomé and Vicente Carreño
Ver en: http://jcm.asm.org/content/52/8/3053
Seronegative occult hepatitis C virus infection: clinical implications.
Carreño V. J Clin Virol. 2014 Nov;61(3):315-20.
Ver en: http://www.journalofclinicalvirology.com/article/S1386-6532(14)00352-7/fulltext
Underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients.
Bartolomé J, Castillo I, Quiroga JA, Carreño V. J Hepatol. 2014 Nov;61(5):1184-5.
Ver en: http://www.journal-of-hepatology.eu/article/S0168-8278(14)00553-4/fulltext
High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies.
Castillo I, Martinez-Ara J, Olea T, Bartolomé J, Madero R, Hernández E, Bernis C, Aguilar A, Quiroga JA, Carreño V, Selgas R. Kidney Int. 2014 Sep;86(3):619-24
Ver en: http://www.kidney-international.theisn.org/article/S0085-2538(15)30321-5/fulltext
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh ML, Hennequi M, Zerr P, Honnet G, Inchauspé G, Agathon D, Limacher JM, Wedemeyer H. Gastroenterology. 2014 Jul;147(1):119-131
Ver en: http://www.gastrojournal.org/article/S0016-5085(14)00356-4/fulltext?referrer=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2F
Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.
Carreño V. Aliment Pharmacol Ther. 2014 Jan;39(2):148-62.
High prevalence of occult hepatitis C virus infection in patients with chronic hepatitis B virus infection.
Castillo I, Bartolomé J, Quiroga JA, Carreño V. J Med Microbiol. 2013 Aug;62(Pt 8):1235-8.
